TY - JOUR
T1 - Multi-modality data-driven analysis of diagnosis and treatment of psoriatic arthritis
AU - Xu, Jing
AU - Ou, Jiarui
AU - Li, Chen
AU - Zhu, Zheng
AU - Li, Jian
AU - Zhang, Hailun
AU - Chen, Junchen
AU - Yi, Bin
AU - Zhu, Wu
AU - Zhang, Weiru
AU - Zhang, Guanxiong
AU - Gao, Qian
AU - Kuang, Yehong
AU - Song, Jiangning
AU - Chen, Xiang
AU - Liu, Hong
N1 - Funding Information:
This work was supported by the National Key Research and Development Program of China (Nos. 2019YFE0120800 and 2019YFA0111600), the Natural Science Foundation of China for outstanding Young Scholars (No. 82022060), the National Natural Science Foundation of China (81902149, 81874242, 31800979, 82073145, 82073447), the Natural Science Foundation of Hunan Province for Outstanding Young Scholars (No. 2019JJ30040), Talent Young Scholars of Hunan Province (No. 2019RS2009), and Natural Science Foundation of Hunan Province (2020JJ5892). CL was supported by a National Health and Medical Research Council of Australia (NHMRC) CJ Martin Early Career Research Fellowship (1143366). Figure was partially created with BioRender.com. We thank the reviewers for their constructive and insightful comments during the peer-review process.
Publisher Copyright:
© 2023, The Author(s).
PY - 2023/12
Y1 - 2023/12
N2 - Psoriatic arthritis (PsA) is associated with psoriasis, featured by its irreversible joint symptoms. Despite the significant impact on the healthcare system, it is still challenging to leverage machine learning or statistical models to predict PsA and its progression, or analyze drug efficacy. With 3961 patients’ clinical records, we developed a machine learning model for PsA diagnosis and analysis of PsA progression risk, respectively. Furthermore, general additive models (GAMs) and the Kaplan–Meier (KM) method were applied to analyze the efficacy of various drugs on psoriasis treatment and inhibiting PsA progression. The independent experiment on the PsA prediction model demonstrates outstanding prediction performance with an AUC score of 0.87 and an AUPR score of 0.89, and the Jackknife validation test on the PsA progression prediction model also suggests the superior performance with an AUC score of 0.80 and an AUPR score of 0.83, respectively. We also identified that interleukin-17 inhibitors were the more effective drug for severe psoriasis compared to other drugs, and methotrexate had a lower effect in inhibiting PsA progression. The results demonstrate that machine learning and statistical approaches enable accurate early prediction of PsA and its progression, and analysis of drug efficacy.
AB - Psoriatic arthritis (PsA) is associated with psoriasis, featured by its irreversible joint symptoms. Despite the significant impact on the healthcare system, it is still challenging to leverage machine learning or statistical models to predict PsA and its progression, or analyze drug efficacy. With 3961 patients’ clinical records, we developed a machine learning model for PsA diagnosis and analysis of PsA progression risk, respectively. Furthermore, general additive models (GAMs) and the Kaplan–Meier (KM) method were applied to analyze the efficacy of various drugs on psoriasis treatment and inhibiting PsA progression. The independent experiment on the PsA prediction model demonstrates outstanding prediction performance with an AUC score of 0.87 and an AUPR score of 0.89, and the Jackknife validation test on the PsA progression prediction model also suggests the superior performance with an AUC score of 0.80 and an AUPR score of 0.83, respectively. We also identified that interleukin-17 inhibitors were the more effective drug for severe psoriasis compared to other drugs, and methotrexate had a lower effect in inhibiting PsA progression. The results demonstrate that machine learning and statistical approaches enable accurate early prediction of PsA and its progression, and analysis of drug efficacy.
UR - http://www.scopus.com/inward/record.url?scp=85147249066&partnerID=8YFLogxK
U2 - 10.1038/s41746-023-00757-3
DO - 10.1038/s41746-023-00757-3
M3 - Article
C2 - 36732611
AN - SCOPUS:85147249066
VL - 6
JO - npj Digital Medicine
JF - npj Digital Medicine
SN - 2398-6352
IS - 1
M1 - 13
ER -